EMA begins rolling review of Moderna’s COVID-19 vaccine candidate
Moderna also announced a supply agreement with the UK government to supply mRNA-1273, if approved for use by MHRA
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
mRNA-1273
Moderna, Pfizer raise bar for COVID-19 vaccines, may ward off competing candidates: GlobalData
While the most effective vaccines will ramp up production to meet global demand, the opportunity for less effective vaccines will…
Moderna publishes interim results from older adults in phase 1 study of its COVID-19 vaccine
At the 25 µg and 100 µg dose levels, mRNA-1273 was generally well-tolerated in all age cohorts, neutralizing antibody titers and T…
Moderna would seek EUA in US for COVID-19 vaccine based on early data
If the interim readout is deemed by the independent safety committee as positive with 70 or 80 or 90 per cent efficacy, we will…
Moderna to set up commercial organisation in Switzerland
Appoints Dan Staner as Vice President and General Manager, Switzerland
Moderna informs COVID-19 vaccine induced immune response in older adults in small study
The latest data from an early Phase I study includes an analysis from 20 additional people detailing how the vaccine performed in…
Moderna begins Phase 3 trials of its COVID-19 vaccine candidate
The randomised, placebo-controlled trial is expected to include approximately 30,000 participants in the US
Moderna and Catalent announce collaboration for COVID-19 vaccine candidate
Catalent to provide vial filling and packaging capacity, as well as additional staffing to support the production of an initial…
Moderna and Lonza collaborate to manufacture mRNA vaccine against COVID-19
Collaboration goal to produce up to one billion doses per year, first batches expected to be manufactured at Lonza US in July 2020